| Filed On | Filing |
|---|---|
| 12 Jul 2024 |
8-K/A: Other Events
As previously reported, on February 27, 2024, CNS Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company... |
| 20 Jun 2024 |
8-K/A: Financial Statements and Exhibits
We have acted as counsel to CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), in connection with the Registration Statement on Form S-3, Registration No. 333-279285 (as amended, the “Registration Statement”), filed by the ... |
| 16 Sep 2020 | 8-K/A: Regulation FD Disclosure |
Loading...
